- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback